The mechanism is real; the human evidence is a hole. In a cell, luteolin blocks IgE-triggered histamine release from mast cells at low doses 1 and shuts down the inflammation loop in microglia, the brain's immune cells 2. But it absorbs poorly, and blood levels land far under what the dish assays use 3. The one suggestive human study was open-label, multi-ingredient, and run by the formulation's patent-holder 4. That doesn't make it placebo. It means nobody can tell you it isn't.
This is a narrow tool, not a general supplement. It plausibly fits people whose symptoms run through histamine: mast cell activation, chronic hives, or histamine intolerance not fully controlled by antihistamines; allergic rhinitis as an add-on; post-COVID brain fog that worsens after meals and tracks with flushing. For a healthy adult wanting "less inflammation," five servings of vegetables move your markers more reliably than 200 mg of any single flavone 5.
If you fit, run one clean trial. The whole game is absorption and patience.
For histamine-driven symptoms the first-line tools are cheaper and better-proven: H1 antihistamines, then adding an H2 blocker like famotidine, then prescription cromolyn from a specialist. Quercetin is the related flavone people often try instead. Generic luteolin runs $20 to $40 a month.
The fine print — when to skip it, and what people get wrong
Luteolin blocks CYP3A4, the enzyme that clears about half of all prescription drugs — statins, transplant meds, many others 6. Tell the prescriber. Skip it in pregnancy and breastfeeding; no human safety data there.
Luteolin is not lutein — lutein is the eye carotenoid in egg yolks, a different molecule for a different job. And eating more parsley isn't the supplement: dietary luteolin is one or two milligrams a day, hundreds of times below the capsule.
- 1Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H (2000). Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clinical and Experimental Allergy. link
- 2Jang S, Kelley KW, Johnson RW (2008). Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proceedings of the National Academy of Sciences USA. link
- 3Shimoi K, Okada H, Furugori M, Goda T, Takase S, Suzuki M, Hara Y, Yamamoto H, Kinae N (1998). Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Letters. link
- 4Taliou A, Zintzaras E, Lykouras L, Francis K (2013). An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clinical Therapeutics. link
- 5Wang Z, Zeng M, Wang Z, Qin F, Chen J, He Z (2021). Dietary luteolin: A narrative review focusing on its pharmacokinetic properties and effects on glycolipid metabolism. Journal of Agricultural and Food Chemistry. link
- 6Quintieri L, Bortolozzo S, Stragliotto S, Moro S, Pavanetto M, Nassi A, Palatini P, Floreani M (2011). Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. Biochemical Pharmacology. link
Luteolin (a flavone supplement for histamine and brain fog)
One or two capsules twice daily, taken with a fat-containing meal — absorption is lipid-dependent <cite data-ref="Shimoi1998">Shimoi et al. 1998</cite> <cite data-ref="Wang2021">Wang et al. 2021</cite>.
Generic luteolin capsules run roughly $20–40/month; branded mast-cell formulations (NeuroProtek, PureLut) closer to $40–80/month — ongoing spend of roughly $240–960/year.
In-vitro mast-cell stabilization at low micromolar concentrations <cite data-ref="Kimata2000">Kimata et al. 2000</cite> plausibly underlies the histamine-symptom reductions reported in MCAS / chronic urticaria communities; the one 26-week open-label autism trial of a luteolin-quercetin-rutin formulation paired behavioural improvement with reduced serum TNF and IL-6 <cite data-ref="Tsilioni2015">Tsilioni et al. 2015</cite>. No blinded RCT in any indication.
Mechanistic literature is dense and replicated across labs <cite data-ref="Aziz2018">Aziz et al. 2018</cite> <cite data-ref="Kimata2000">Kimata et al. 2000</cite>, but human evidence is two single-arm open-label trials of a multi-component formulation from the patent-holder's group <cite data-ref="Taliou2013">Taliou et al. 2013</cite> <cite data-ref="Tsilioni2015">Tsilioni et al. 2015</cite>. No blinded RCT on any clinical endpoint.
Microglial JNK / AP-1 inhibition reduces IL-6 production in vitro <cite data-ref="Jang2008">Jang et al. 2008</cite>, framed as the mechanistic basis for long-COVID brain-fog / neuroinflammation use <cite data-ref="Theoharides2021">Theoharides et al. 2021</cite>. Mechanistic plausibility only — no controlled cognitive-endpoint trial.
Downstream of the neuroinflammation lens; the open-label ASD trial reported behavioural and adaptive-function gains <cite data-ref="Taliou2013">Taliou et al. 2013</cite> alongside cytokine reductions <cite data-ref="Tsilioni2015">Tsilioni et al. 2015</cite>. Mechanism plausible, controlled human evidence absent.